Overview

Evaluate F901318 Treatment of Invasive Fungal Infections in Patients Lacking Treatment Options

Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
A study to evaluate F901318 (study drug) for the treatment of invasive fungal infections in patients lacking suitable alternative treatment options.
Phase:
Phase 2
Details
Lead Sponsor:
F2G Biotech GmbH
F2G Ltd.
Collaborators:
IQVIA
Iqvia Pty Ltd
Treatments:
Olorofim